Velagliflozin

Last updated

Velagliflozin
Velagliflozin structure.svg
Clinical data
Trade names Senvelgo
License data
Routes of
administration 		By mouth
ATCvet code
Legal status
Legal status
Identifiers
  • 2-[(4-cyclopropylphenyl)methyl]-4-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]benzonitrile
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C23H25NO5
Molar mass 395.455 g·mol−1
3D model (JSmol)
  • N#Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(C2CC2)cc1
  • InChI=1S/C23H25NO5/c24-11-17-8-7-16(23-22(28)21(27)20(26)19(12-25)29-23)10-18(17)9-13-1-3-14(4-2-13)15-5-6-15/h1-4,7-8,10,15,19-23,25-28H,5-6,9,12H2/t19-,20-,21+,22-,23+/m1/s1
  • Key:SENUNDCNOYAWGN-ZQGJOIPISA-N
  • Key:UWKBFNWQMSGEPG-ZHNCTCHCSA-N

Velagliflozin, sold under the brand name Senvelgo, is an antidiabetic medication used for the treatment of cats. [2] [4] [5] Velagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. [6] It is taken by mouth. [2]

Medical uses

Velagliflozin is indicated to improve glycemic control in otherwise healthy cats with diabetes not previously treated with insulin. [2] [4] [6]

References

  1. ↑ "Notice: Multiple additions to the Prescription Drug List (PDL) [2024-10-18]". Health Canada . 18 October 2024. Retrieved 25 October 2024.
  2. 1 2 3 4 "Senvelgo- velagliflozin solution". DailyMed. 8 November 2023. Retrieved 13 December 2023.
  3. ↑ "Senvelgo Product information". Union Register of veterinary medicinal products. 22 November 2023. Retrieved 29 August 2024.
  4. 1 2 "NADA 141-568 Senvelgo (velagliflozin oral solution) Cats".PD-icon.svg This article incorporates text from this source, which is in the public domain .
  5. ↑ Cook AK, Behrend E (January 2025). "SGLT2 inhibitor use in the management of feline diabetes mellitus". Journal of Veterinary Pharmacology and Therapeutics. 48 Suppl 1 (Suppl 1): 19–30. doi:10.1111/jvp.13466. PMC   11736986 . PMID   38954371.
  6. 1 2 "Dear Veterinarian Letter regarding important safety conditions associated with the use of Senvelgo (velagliflozin oral solution) for improving glycemic control in certain cats with diabetes mellitus". U.S. Food and Drug Administration. 4 December 2023. Retrieved 13 December 2023.PD-icon.svg This article incorporates text from this source, which is in the public domain .


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.